1. Home
  2. VATE vs BLRX Comparison

VATE vs BLRX Comparison

Compare VATE & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo INNOVATE Corp.

VATE

INNOVATE Corp.

HOLD

Current Price

$4.54

Market Cap

70.3M

Sector

Industrials

ML Signal

HOLD

Logo BioLineRx Ltd.

BLRX

BioLineRx Ltd.

N/A

Current Price

$3.17

Market Cap

17.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VATE
BLRX
Founded
1994
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
70.3M
17.1M
IPO Year
1996
2011

Fundamental Metrics

Financial Performance
Metric
VATE
BLRX
Price
$4.54
$3.17
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$19.00
AVG Volume (30 Days)
14.4K
28.4K
Earning Date
11-12-2025
11-24-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,099,900,000.00
$12,735,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.05
$2.30
52 Week High
$13.79
$14.70

Technical Indicators

Market Signals
Indicator
VATE
BLRX
Relative Strength Index (RSI) 32.98 46.97
Support Level $4.76 $3.16
Resistance Level $5.28 $3.43
Average True Range (ATR) 0.24 0.22
MACD -0.07 0.01
Stochastic Oscillator 24.99 26.03

Price Performance

Historical Comparison
VATE
BLRX

About VATE INNOVATE Corp.

Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments which are; The infrastructure segment is comprised of DBM Global Inc, a fully integrated industrial construction, structural steel, and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services, The Life Sciences segment is comprised of Pansend Life Sciences which seeks to develop products to treat early osteoarthritis of the knee and aesthetic and medical technologies for the skin, and Spectrum segment is comprised of HC2 Broadcasting Holdings Inc which operates over-the-air broadcasting station across the United States.

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: